Stock ATNM ACTINIUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
6.87 USD +4.73% Intraday chart for Actinium Pharmaceuticals, Inc. +0.29% +35.24%
Apr. 26 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 18 Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting CI

Business Summary

Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.

Number of employees: 49

Sales per Business

USD in Million2022Weight2023Weight Delta
Radiotherapies
100.0 %
0 nan % 0 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 0 100.0 % -

Managers

Managers TitleAgeSince
Sandesh Seth CEO
 Chief Executive Officer 60 12-02-29
Steve O'Loughlin DFI
 Director of Finance/CFO 39 15-10-12
Akash Nahar CTO
 Chief Tech/Sci/R&D Officer - 22-10-26
Monideepa Roy CTO
 Chief Tech/Sci/R&D Officer - 21-09-26
Mary Mei Chen CTO
 Chief Tech/Sci/R&D Officer - 20-11-30
Avinash Desai CTO
 Chief Tech/Sci/R&D Officer - 20-11-18
Stephen Dressel PRN
 Corporate Officer/Principal - -
Sunitha Lakshminarayanan PRN
 Corporate Officer/Principal - -
Jenny Hsieh PRN
 Corporate Officer/Principal - -
Paul Diamond LAW
 General Counsel - 21-06-30

Members of the board

Members of the board TitleAgeSince
Richard Steinhart BRD
 Director/Board Member 66 13-11-07
C. Nicholson BRD
 Director/Board Member 68 07-12-31
Ajit Shetty BRD
 Director/Board Member 77 17-03-27
Sandesh Seth CEO
 Chief Executive Officer 60 12-02-29
Jeffrey Chell BRD
 Director/Board Member 70 18-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 29,396,411 28,760,771 ( 97.84 %) 0 97.84 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
5.851 %
1,624,526 5.851 % 13 M $
Vanguard Fiduciary Trust Co.
4.914 %
1,364,213 4.914 % 11 M $
Michael Bigger
3.849 %
1,068,774 3.849 % 8 M $
District 2 Capital LP
2.977 %
826,428 2.977 % 6 M $
Geode Capital Management LLC
2.051 %
569,549 2.051 % 4 M $
STATE STREET CORPORATION
1.826 %
506,842 1.826 % 4 M $
Northern Trust Investments, Inc.(Investment Management)
0.7499 %
208,194 0.7499 % 2 M $
Sentinus LLC
0.6025 %
167,275 0.6025 % 1 M $
Dimensional Fund Advisors LP
0.5310 %
147,437 0.5310 % 1 M $
Brandywine Global Investment Management LLC
0.5244 %
145,600 0.5244 % 1 M $

Company contact information

Actinium Pharmaceuticals, Inc.

100 Park Avenue 23rd floor

10017, New York

+646 677 3870

http://www.actiniumpharma.com
address Actinium Pharmaceuticals, Inc.(ATNM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Actinium Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
6.87 USD
Average target price
25.47 USD
Spread / Average Target
+270.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ACTINIUM PHARMACEUTICALS, INC. Stock Actinium Pharmaceuticals, Inc.
+35.24% 202M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ATNM Stock
  4. Company Actinium Pharmaceuticals, Inc.